United States FDA Clears Mesoblast Limited (ASX:MSB) Trial For Cervical Spinal Fusion Phase 2
Mesoblast's Phase 2 cervical fusion clinical program will compare two doses of NeoFuse(TM) versus standard-of-care in 36 patients requiring bony fusion at two or more levels in the cervical spine.

Vatican Endorsement Seals NBS's Status as a The Major Play in Regenerative Medicine
Just as we have speculated in articles and trade alerts for the past few weeks, the Roman Catholic church appears to be getting ready to support Neostem's (AMEX:NBS) stem cell initiatives[...]

• Scientific American Topic - Gene Therapy

  Realistic stem cell therapies to replace diseased or damaged tissue may still be years away, but researchers have uncovered a promising new use for these undifferentiated cells: they can be programmed to become patient-specific laboratory models of inherited liver disease.[…]

  Read more...
• NYT > Stem Cells

  The head of the National Institutes of Health said a judge’s decision would most likely force the cancellation of dozens of experiments in diseases ranging from diabetes to Parkinson’s.

  Read more...
• Scientific American Topic - Gene Therapy

  Down's syndrome (DS) is an incurable, heritable disorder affecting an estimated 400,000 people in the U.S. It is characterized by impaired cognitive ability and abnormal physical growth. Whereas scientists have long known that DS is caused by inheriting an extra[…]

  Read more...
• Stem Cells Current Events and Stem Cells News from Brightsurf

  Female induced pluripotent stem (iPS) cells, reprogrammed from human skin cells into cells that have the embryonic-like potential to become any cell in the body, retain an inactive X chromosome, stem cell researchers at UCLA have found. (2010-09-03)

  Read more...